ClinicalTrials.gg
CompletedNCT01970111Updated Apr 18, 2016

An Extension Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

A Phase 3 interventional study of KPS-0373, High dose and KPS-0373, Low dose in Spinocerebellar Degeneration, sponsored by Kissei Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2016-04-18.

Sponsored by Kissei Pharmaceutical Co., Ltd. · Phase 3 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Spinocerebellar Degenerations with a site in Japan — none open to participants now, 1 under way, 1 of them phase 3. Spinocerebellar Degenerations · Japan.

Phase 3
7 of 11
none open now
Registered
4th of 11
by date
Lead sponsor
9 of 11
Kissei Pharmaceutical Co., Ltd.

Among the 11 studies in Spinocerebellar Degenerations with a site in Japan, this one is one of 7 in phase 3, and was the 4th registered.

Spinocerebellar Degenerations

49 studies on the registry are indexed under Spinocerebellar Degenerations; 15 are open to participants now.

Browse Spinocerebellar Degenerations studies →

Open to participants now

None of the 11 studies in Spinocerebellar Degenerations with a site in Japan is open now. The open studies under Spinocerebellar Degenerations, anywhere →

Who these studies take

Of the 9 Spinocerebellar Degenerations studies recruiting now, 5 set no upper age limit and 3 stop at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: 20 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Spinocerebellar Degenerations with a site in Japan as a file.
02

Study summary

The purpose of this study is to evaluate the long-term safety, efficacy, and pharmacokinetics of KPS-0373 in SCD patients.

03

Conditions studied

  • Spinocerebellar Degeneration

Keywords

  • Spinocerebellar degeneration (SCD)
  • Thyrotropin-Releasing Hormone (TRH)
  • Spinocerebellar Ataxia (SCA)
  • Cortical Cerebellar Atrophy (CCA)
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Japanese SCD patients with mild to moderate ataxia (Completion of the KPS1301 study)

Exclusion criteria

Exclusion Criteria:

  • Less than 75% of compliance in KPS1301 study
05

Study design

Phase
Phase 3

Study arms

  • Experimental
    KPS-0373

    Drug: KPS-0373, High dose · Drug: KPS-0373, Low dose

06

What researchers measure

Primary outcomes

  1. SARA (Scale for the Assessment and Rating of Ataxia)

    Time frame: 52 weeks

Secondary outcomes

  1. SF-8 (QOL)

    Time frame: 52 weeks

07

Study locations

1 site
  • Tokyo and Other Japanese Cities, Japan
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 18, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01970111
Responsible party
Sponsor
First posted
Oct 25, 2013
Primary completion
Jul 2015
Last update
Apr 18, 2016
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rovatirelin

Start the discussion